Fundraising FoxAprea
Doylestown, US · 6 known investors
Find your way into Aprea
Sign up to see every warm intro you have to Aprea
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aprea team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development.
Founders & leadership
Board
Investors · 6
How we know: 5AM Ventures's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Robin Hood Ventures's portfolio page · Not right? Tell us
How we know: Rosetta Capital Ltd.'s portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$3.1M disclosed across 1 round · 2025
▶$3.1MraisedDec 2025 · 8 investors · BiotechnologyRule 506(b)
- John P. HamillExecutive Officer
- Jean-Pierre BizzariDirector
- Gabriela GruiaDirector
- Rifat PamukcuDirector
- Bernd SeizingerDirector
- Marc DueyDirector
- John B. HennemanDirector
- Oren GiladExecutive Officer, Director
- Michael GrissingerDirector
- Richard PetersDirector
- Offering amount
- $5.8M
- Amount sold
- $3.1M
- Sales commissions
- $210K
- Placement agents
- Maxim Group LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $862.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Aprea do?
- Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers. The company's lead programs are APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both in clinical development.
- Who are Aprea's investors?
- Aprea's investors include 5AM Ventures, HealthCap, Robin Hood Ventures, Rosetta Capital Ltd., Versant Ventures, Soleus Capital.
- How much funding has Aprea raised?
- Aprea has disclosed $3.1M raised across 1 round.
- Where is Aprea headquartered?
- Aprea is headquartered in Doylestown, US.